ArticleNorthern clinics of Istanbul2025
Effects of levetiracetam monotherapy on thyroid function in pediatric epilepsy patients.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChildhood epilepsy requires long-term antiepileptic drug (AED) therapy, and its potential endocrine effects are a critical consideration. While the impact of AEDs on thyroid function is well documented in adults, data on pediatric populations remain scarce. Levetiracetam (LEV), a broad-spectrum AED widely prescribed for children, has an unclear influence on thyroid function. This study aims to evaluate the effects of LEV on thyroid function in children with epilepsy.
methodsA retrospective observational study was conducted at the Pediatric Neurology Clinic of Umraniye Hospital between 2020 and 2022. One hundred pediatric patients, aged 2.3 to 18 years, diagnosed with epilepsy and using LEV monotherapy for at least 12 months were included. Thyroid-stimulating hormone (TSH) and free thyroxine (fT4) levels were measured at baseline and at 3, 6, and 12 months. Statistical analyses were performed using paired t-tests, with a p-value <0.05 considered statistically significant.
resultsThe mean TSH levels increased from 1.46±0.3 mIU/L at baseline to 1.60±0.3 mIU/L at 12 months (p=0.0017). Despite the statistically significant rise, TSH levels remained within normal reference ranges, and no clinically significant hypothyroidism was observed. Changes in fT4 levels were not statistically significant, except for a borderline increase at 12 months (p=0.05). Four patients exhibited transient TSH elevations but did not require thyroid hormone replacement therapy.
conclusionLEV monotherapy does not appear to significantly impact thyroid function in pediatric epilepsy patients. While a slight but statistically significant increase in TSH levels was observed, these changes were clinically insignificant. These findings suggest that LEV is a safe option regarding thyroid function in children with epilepsy. Further long-term prospective studies are warranted to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.